Su Y F, McNutt R W, Chang K J
Department of Anesthesiology and Pharmacology, Durham, Division of Chemistry, Glaxo Wellcome Co., Research Triangle Park, USA.
J Pharmacol Exp Ther. 1998 Dec;287(3):815-23.
Evidence suggests both opioid mu and delta receptors may participate in the regulation of respiration at different central nervous system sites. In the past, the overlapping receptor specificity of various opioid drugs has made it difficult to dissect the receptor subtype-specific activities involved in respiratory regulation. The new family of delta receptor selective agents such as cyclic[D-Pen2, 5]enkephalin, deltorphins, (+)-4-((alpha-R)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide, naltrindole and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH have now made it feasible to more clearly define the role of delta receptors in respiratory control. In a series of experiments we observed that systemic infusion of rats with the highly mu receptor-specific opioid alfentanil induced antinociception and hypercapnia, and both of these effects were antagonized by the mu antagonist D-Phe-Cys-Tyr-Orn-Thr-Pen-Thr-NH2. However, peripheral administration of the delta receptor antagonist naltrindole reverses the hypercapnia but not the antinociceptive activity of alfentanil. This differential effect of naltrindole on antinociception and hypercapnia could also be produced with the delta agonist (+)-4-((alpha-R)-alpha-((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. In addition, intracerebroventricular delivery of a number of peptide delta ligands cyclic[D-Pen2,5]enkephalin, deltorpnin II and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH also produced the same differential reversal of hypercapnia without affecting antinociception. Thus, both the traditional delta agonists and antagonists are able to reverse the alfentanil-induced hypercapnia without affecting antinociception. The reversal of alfentanil-induced hypercapnia by these delta ligands was antagonized by a novel synthetic delta antagonist cis-4-(alpha-(4-((Z)-2-butenyl)-3, 5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide. We propose that in this experimental respiration model, the delta antagonists naltrindole and H-Tyr-Tic(psi)[CH2NH]Phe-Phe-OH behave like delta agonists with low but sufficient intrinsic activities to reverse alfentanil-induced hypercapnia in rats. The results suggest that a function of the delta receptor is to modulate or counteract the respiratory depression induced by the mu receptor.
有证据表明,阿片类μ受体和δ受体可能在不同的中枢神经系统部位参与呼吸调节。过去,各种阿片类药物重叠的受体特异性使得难以剖析呼吸调节中涉及的受体亚型特异性活性。新型δ受体选择性药物家族,如环[D-青霉胺2,5]脑啡肽、强啡肽、(+)-4-((α-R)-α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-羟基苄基)-N,N-二乙苯甲酰胺、纳曲吲哚和H-酪氨酸-噻唑(ψ)[CH2NH]苯丙氨酸-苯丙氨酸-OH,现在使得更清楚地定义δ受体在呼吸控制中的作用成为可能。在一系列实验中,我们观察到向大鼠全身输注高度μ受体特异性阿片类药物阿芬太尼会诱导抗伤害感受和高碳酸血症,并且这两种效应都被μ拮抗剂D-苯丙氨酸-半胱氨酸-酪氨酸-鸟氨酸-苏氨酸-苯丙氨酸-苏氨酸-NH2所拮抗。然而,外周给予δ受体拮抗剂纳曲吲哚可逆转阿芬太尼的高碳酸血症,但不能逆转其抗伤害感受活性。纳曲吲哚对抗伤害感受和高碳酸血症的这种差异效应也可以用δ激动剂(+)-4-((α-R)-α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-羟基苄基)-N,N-二乙苯甲酰胺产生。此外,向脑室内递送多种肽类δ配体环[D-青霉胺2,5]脑啡肽、强啡肽II和H-酪氨酸-噻唑(ψ)[CH2NH]苯丙氨酸-苯丙氨酸-OH也产生了相同的高碳酸血症差异逆转,而不影响抗伤害感受。因此,传统的δ激动剂和拮抗剂都能够逆转阿芬太尼诱导的高碳酸血症,而不影响抗伤害感受。这些δ配体对阿芬太尼诱导的高碳酸血症的逆转作用被新型合成δ拮抗剂顺式-4-(α-(4-((Z)-2-丁烯基)-3,5-二甲基-1-哌嗪基)-3-羟基苄基)-N,N-二乙苯甲酰胺所拮抗。我们提出,在这个实验性呼吸模型中,δ拮抗剂纳曲吲哚和H-酪氨酸-噻唑(ψ)[CH2NH]苯丙氨酸-苯丙氨酸-OH的行为类似于具有低但足够内在活性的δ激动剂,以逆转大鼠中阿芬太尼诱导的高碳酸血症。结果表明,δ受体的一个功能是调节或抵消由μ受体诱导的呼吸抑制。